BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 202.5 USD | +0.23% |
|
+6.27% | -21.76% |
| Apr. 25 | Goldman Sachs Adjusts Biogen Price Target to $340 From $393 | MT |
| Apr. 25 | Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
202.5
USD
Average target price
286.5
USD
Spread / Average Target
+41.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.76% | 29.36B | |
| -2.86% | 87.31B | |
| +2.63% | 40.86B | |
| +58.56% | 24.49B | |
| -14.78% | 17.31B | |
| -18.49% | 11.62B | |
| -15.61% | 11.31B | |
| -44.02% | 11.26B | |
| +5.17% | 8.31B | |
| -9.82% | 7.9B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosis Drug
